« Return to News | R&D Trends

Evotec, IR Pharma partner for respiratory disease drug discovery

Friday, February 17, 2012 01:41 PM

Evotec and IR Pharma have formed an exclusive strategic alliance to provide integrated drug discovery solutions to pharmaceutical and biotech companies in the field of respiratory diseases.

The alliance expands Evotec's drug discovery platform into the area of respiratory diseases through IR Pharma's expertise in in vitro and in vivo respiratory pharmacology. Evotec can now offer fully-integrated respiratory- and inflammation-focused drug discovery programs to its partners, from target to nomination of pre-clinical development candidates.

"IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models, and coupled with our world-leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas,” said Dr. Mario Polywka, COO at Evotec.

Maria Belvisi, director at IR Pharma, added, "We have a range of highly validated models, focusing on asthma, cough and Chronic Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's platform, thus enabling a fully integrated approach to drug discovery in this challenging area."

No financial details were disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.